通过血清蛋白质组分析检测系统性硬化症相关肺动脉高压血流动力学严重程度的生物标志物
本研究对无广泛间质性肺病且未接受PAH特异性治疗的局限性皮肤型系统性硬化症患者进行血清蛋白质组分析,以右心导管确诊的PAH为病例组。高通量检测发现chemerin和SET与肺血管阻力相关,独立队列ELISA验证chemerin水平显著升高并与PVR相关。作者认为chemerin可能是SSc-PAH中PVR的替代生物标志物。
要点
- 在SSc-PAH患者中,chemerin和SET与肺血管阻力显著相关。
- 独立队列证实SSc-PAH患者血清chemerin水平显著升高并与PVR相关。
- Chemerin可能通过CMKLR1诱导肺动脉平滑肌细胞增殖参与SSc-PAH发病。
核心结论
- Chemerin似乎是SSc-PAH中PVR的一个有意义的替代生物标志物。
- 血清chemerin水平升高和PA-SMCs上CMKLR1表达增加可能通过诱导PA-SMC增殖参与SSc-PAH发病。
研究设计与样本
- 纳入无广泛间质性肺病且未接受PAH特异性治疗的局限性皮肤型SSc患者,以右心导管确诊PAH且同日采集血清者为病例,无PAH临床证据者为对照。
- 采用高通量蛋白质组学检测(SOMAscan)评估1129种蛋白质,并在独立队列中用ELISA验证chemerin。
主要发现
- 在SSc-PAH患者(n=15)中,1129种蛋白质中仅2种差异表达并与PVR显著相关:chemerin(ρ=0.62,p=0.01)和SET(ρ=0.62,p=0.01)。
- 独立队列中SSc-PAH患者(n=24)chemerin水平显著升高(p=0.01)且与PVR相关(ρ=0.42,p=0.04)。
- 单细胞RNA测序在SSc-PAH肺组织的成纤维细胞、PA-SMCs/周细胞和间皮细胞中检测到chemerin mRNA表达。
- 共聚焦免疫荧光显示SSc-PAH的PA-SMCs上chemerin受体CMKLR1表达增加。
- SSc-PAH血清似乎比无PAH的SSc患者血清诱导更高的PA-SMC增殖,加入CMKLR1抑制剂α-NETA后该差异似乎被中和。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To mine the serum proteome of patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) and to detect biomarkers that may assist in earlier and more effective diagnosis and treatment. METHODS: Patients with limited cutaneous SSc, no extensive interstitial lung disease and no PAH-specific therapy were included. They were classified as cases if they had PAH confirmed by right heart catheterisation (RHC) and serum collected on the same day as RHC; and as controls if they had no clinical evidence of PAH. RESULTS: Patients were mostly middle-aged females with anticentromere-associated SSc. Among 1129 proteins assessed by a high-throughput proteomic assay (SOMAscan), only 2 were differentially expressed and correlated significantly with pulmonary vascular resistance (PVR) in SSc-PAH patients (n=15): chemerin (ρ=0.62, p=0.01) and SET (ρ=0.62, p=0.01). To validate these results, serum levels of chemerin were measured by ELISA in an independent cohort. Chemerin levels were confirmed to be significantly higher (p=0.01) and correlate with PVR (ρ=0.42, p=0.04) in SSc-PAH patients (n=24). Chemerin mRNA expression was detected in fibroblasts, pulmonary artery smooth muscle cells (PA-SMCs)/pericytes and mesothelial cells in SSc-PAH lungs by single-cell RNA-sequencing. Confocal immunofluorescence revealed increased expression of a chemerin receptor, CMKLR1, on SSc-PAH PA-SMCs. SSc-PAH serum seemed to induce higher PA-SMC proliferation than serum from SSc patients without PAH. This difference appeared neutralised when adding the CMKLR1 inhibitor α-NETA. CONCLUSION: Chemerin seems an interesting surrogate biomarker for PVR in SSc-PAH. Increased chemerin serum levels and CMKLR1 expression by PA-SMCs may contribute to SSc-PAH pathogenesis by inducing PA-SMC proliferation.
引用
- Sanges S, Rice L, Tu L, et al. Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis. Ann Rheum Dis. 2022. PMID: 36600187. doi:10.1136/ard-2022-223237
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。